Effectiveness of teriparatide in women over 75 years of age with severe osteoporosis: 36-month results from the European Forsteo Observational Study (EFOS)

Calcified Tissue International

Volumn 90, Issue 5, 2012, Pages 373-383

  Walsh, J Bernard ^a   Lems, Willem F ^b   Karras, Dimitrios ^c   Langdahl, Bente L ^d   Ljunggren, Osten ^e   Fahrleitner Pammer, Astrid ^f   Barrett, Annabel ^g   Rajzbaum, Gerald ^h   Jakob, Franz ⁱ   Marin, Fernando ^g  

^a ST JAMES S HOSPITAL   (Ireland)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Veterans Administration Hospital   (Greece)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e UPPSALA UNIVERSITY   (Sweden)

^f MEDICAL UNIVERSITY OF GRAZ   (Austria)

^g ELI LILLY AND COMPANY   (United States)

^h SAINT JOSEPH HOSPITAL   (France)

ⁱ UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Age; Back pain; Fracture; Health related quality of life; Osteoporosis; Teriparatide

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; PARATHYROID HORMONE[1-34]; VITAMIN D;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BACKACHE; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE SEVERITY; FEMALE; FRAGILITY FRACTURE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PAIN ASSESSMENT; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RISK REDUCTION; TREATMENT DURATION; VERTEBRA FRACTURE; VISUAL ANALOG SCALE;

AGED; AGED, 80 AND OVER; BACK PAIN; BONE DENSITY CONSERVATION AGENTS; FEMALE; FRACTURES, BONE; HUMANS; LOGISTIC MODELS; OSTEOPOROSIS, POSTMENOPAUSAL; QUALITY OF LIFE; TERIPARATIDE;

EID: 84859903226     PISSN: 0171967X     EISSN: 14320827     Source Type: Journal    
DOI: 10.1007/s00223-012-9590-9     Document Type: Article

References (34)

1. O Johnell JA Kanis 2006 An estimate of the worldwide prevalence and disability associated with osteoporotic fractures Osteoporos Int 17 1726 1733 16983459 10.1007/s00198-006-0172-4 1:STN:280:DC%2BD28nitVSksQ%3D%3D (Pubitemid 44607392)
2. D Bliuc ND Nguyen VE Milch TV Nguyen JA Eisman JR Center 2009 Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women JAMA 301 513 521 19190316 10.1001/jama.2009.50 1:CAS:528:DC%2BD1MXhtlyqs7Y%3D
3. P Haentjens J Magaziner CS Colon-Emeric D Vanderschueren K Milisen B Velkeniers S Boonen 2010 Meta-analysis: excess mortality after hip fracture in older women and men Ann Intern Med 152 380 390 20231569
4. RM Francis TJ Aspray G Hide AM Sutcliffe P Wilkinson 2008 Back pain in osteoporotic vertebral fractures Osteoporos Int 19 895 903 18071648 10.1007/s00198-007-0530-x 1:STN:280:DC%2BD1czkvVSguw%3D%3D
5. P Lips NM van Schoor 2005 Quality of life in patients with osteoporosis Osteoporos Int 16 447 455 15609073 10.1007/s00198-004-1762-7
6. AM Oleksik S Ewing W Shen NM van Schoor P Lips 2005 Impact of incident vertebral fractures on health related quality of life (HRQOL) in postmenopausal women with prevalent vertebral fractures Osteoporos Int 16 861 870 15558238 10.1007/s00198-004-1774-3 (Pubitemid 41127094)
7. G Albrand F Munoz E Sornay-Rendu F DuBoeuf PD Delams 2003 Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: the OFELY study Bone 32 78 85 12584039 10.1016/S8756-3282(02)00919-5 1:STN:280:DC%2BD3s%2FntlajsA%3D%3D (Pubitemid 36173815)
8. J Finigan DM Greenfield A Blumsohn RA Hannon NF Peel G Jiang R Eastell 2008 Risk factors for vertebral and nonvertebral fracture over 10 years: a population-based study in women J Bone Miner Res 23 75 85 17784843 10.1359/jbmr.070814
9. JA Kanis N Burlet C Cooper PD Delmas JY Reginster F Borgstrom R Rizzoli 2008 European guidance for the diagnosis and management of osteoporosis in postmenopausal women Osteoporos Int 19 399 428 18266020 10.1007/s00198-008-0560- z 1:STN:280:DC%2BD1c3itFekuw%3D%3D
10. ES Siris SK Brenneman E Barrett-Connor PD Miller S Sajjan ML Berger YT Chen 2006 The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50-99: results from the National Osteoporosis Risk Assessment (NORA) Osteoporos Int 17 565 574 16392027 10.1007/s00198-005-0027-4 1:STN:280:DC%2BD287msF2msg%3D%3D
11. United Nations Department of Economic and Social Affairs, Population Division. World Population Ageing (2007) www.un.org/esa/population/publications/ WPA2007/wpp2007.htm. Accessed 31 May 2011
12. Boonen S (2008) Medical treatment of age-related osteoporosis: present and future. In: Duque G, Kiel DP (eds) Osteoporosis in older persons-pathophysiology and therapeutic approach. Springer, London, pp 137-152
13. MC Chapuy ME Arlot F Duboeuf J Brun B Crouzet S Arnaud PD Delmas PJ Meunier 1992 Vitamin D3 and calcium to prevent hip fractures in the elderly women N Engl J Med 327 1637 1642 1331788 10.1056/NEJM199212033272305 1:STN:280:DyaK3s%2FmtlSrug%3D%3D
14. KE Ensrud DM Black L Palermo DC Bauer E Barrett-Connor SA Quandt DE Thompson DB Karpf 1997 Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial Arch Intern Med 157 2617 2624 9531231 10.1001/archinte.1997.00440430099012 1:CAS:528: DyaK2sXotVCksrg%3D (Pubitemid 27519982)
15. S Boonen MR McClung R Eastell GE-H Fuleihan IP Barton P Delmas 2004 Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old J Am Geriatr Soc 52 1832 1839 15507059 10.1111/j.1532-5415.2004.52506.x (Pubitemid 41710266)
16. S Boonen DM Black CS Colon-Emeric R Eastell JS Magaziner EF Eriksen P Mesenbrink P Haentjens KW Lyles 2010 Efficacy and safety of a once-yearly intravenous zolendronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older J Am Geriatr Soc 58 292 299 20070415 10.1111/j.1532-5415.2009.02673.x
17. S Boonen AB Klemes X Zhou R Lindsay 2010 Assessment of the relationship between age and the effect of risedronate treatment in women with postmenopausal osteoporosis: a pooled analysis of four studies J Am Geriatr Soc 58 658 663 20345865 10.1111/j.1532-5415.2010.02763.x
18. E Seeman B Vellas C Benhamou JP Aquino J Semler JM Kaufman K Hoszowski AR Varela C Fiore K Brixen JY Reginster S Boonen 2006 Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older J Bone Miner Res 21 1113 1120 16813532 10.1359/jbmr.060404 1:CAS:528:DC%2BD28XntlWqu7k%3D (Pubitemid 43962840)
19. E Seeman S Boonen F Borgstrom B Vellas JP Aquino J Semler C-L Benhamou J-M Kaufman J-Y Reginster 2010 Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age Bone 46 1038 1042 20026265 10.1016/j.bone.2009.12.006 1:CAS:528:DC%2BC3cXjs1aksLg%3D
20. S Boonen JD Adachi Z Man SR Cummings K Lippuner O Torring JC Gallagher J Farrerons A Wang N Franchimont J San Martin A Grauer M McClung 2011 Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk J Clin Endocrinol Metab 96 1727 1736 21411557 10.1210/jc.2010-2784 1:CAS:528:DC%2BC3MXnt1ChsLo%3D
21. S Boonen F Marin D Mellstrom L Xie D Desaiah JH Krege CJ Rosen 2006 Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective J Am Geriatr Soc 54 782 789 16696744 10.1111/j.1532-5415.2006.00695.x (Pubitemid 44030200)
22. SL Silverman 2009 From randomised controlled trials to observational studies Am J Med 122 114 120 19185083 10.1016/j.amjmed.2008.09.030
23. G Rajzbaum F Jakob D Karras O Ljunggren WF Lems BL Langdahl A Fahrleitner-Pammer JB Walsh A Gibson AJ Tynan F Marin 2007 Characterization of patients in the European Forsteo Observational Study (EFOS): postmenopausal women entering teriparatide treatment in a community setting Curr Med Res Opin 24 377 384 10.1185/030079908X261087 (Pubitemid 351294388)
24. A Fahrleitner-Pammer B Langdahl F Marin F Jakob D Karras A Barrett O Ljunggren JB Walsh G Rajzbaum C Barker WF Lems 2011 Fracture rate and back pain during and after discontinuation of teriparatide: 36 month data from the European Forsteo Observational Study (EFOS) Osteoporos Int 22 2709 2719 21113576 10.1007/s00198-010-1498-5 1:STN:280:DC%2BC3MfitVOhuw%3D%3D
25. European Medicines Agency (2009) Forsteo (teriparatide). http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/ 000425/human-med-000798.jsp&murl=menus/medicines/medicines. jsp&jsenabled=true. Accessed 25 March 2011
26. PD Ross 1997 Clinical consequences of vertebral fractures Am J Med 103 2A 30S 42S 9302895 10.1016/S0002-9343(97)90025-5 1:STN:280:DyaK2svkvVGluw%3D%3D
27. R Rabin F de Charro 2001 EQ-5D: a measure of health status from the EuroQol Group Ann Med 33 337 343 11491192 10.3109/07853890109002087 1:STN:280:DC%2BD3MvksFWqsw%3D%3D (Pubitemid 32675374)
28. Szende A, Willams A (2004) Measuring self-reported population health: an international perspective based on the EQ-5D. SpringMed, Budapest
29. KY Laing SL Zeger 1986 Longitudinal data analysis using generalised linear models Biometrika 73 13 22 10.1093/biomet/73.1.13
30. Hosmer DW, Lemeshow S (2002) Applied logistic regression, 2nd edn. Wiley, New York
31. E Seeman 2002 Pathogenesis of bone fragility in women and men Lancet 359 1841 1850 12044392 10.1016/S0140-6736(02)08706-8 (Pubitemid 34607063)
32. P Pietschmann M Rauner W Sipos K Kerschan-Schindl 2009 Osteoporosis: an age-related and gender-specific disease-a mini review Gerontology 55 3 12 18948685 10.1159/000166209
33. MC Hochberg DE Thompson DM Black SA Quandt J Cauley P Geusens PD Ross D Baran The FIT Research Group 2005 Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures J Bone Miner Res 20 971 976 15883637 10.1359/JBMR.050104 1:CAS:528:DC%2BD2MXlsFehtro%3D (Pubitemid 40712821)
34. MV Maraldo P Vestergaard MET McMurdo P Schwarz 2010 The evidence for antiresorptive osteoporosis treatment in the elderly and old Eur Geriatr Med 1 279 292 10.1016/j.eurger.2010.08.002